Study: Despite recommendations, less than 2 percent of patients with treatment-resistant hypertension were tested for primary aldosteronism in a large U.S. cohort
14 Jan, 2021 | 01:55h | UTCTesting for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans: A Retrospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentaries: Primary Aldosteronism Testing Rare in Treatment-Resistant HTN – HealthDay AND Primary Aldosteronism Testing Rare for Patients with Resistant Hypertension – NEJM Journal Watch
Commentary from the author on Twitter (thread – click for more)
Our new study is out in @AnnalsofIM w/@BhallaResearch @thebyrdlab @johnleppert! ?https://t.co/UCrAD4ed0w
We asked: Are patients w/treatment resistant HTN being appropriately tested for primary aldosteronism (PA) & managed w/mineralocorticoid receptor antagonists (MRAs)? 1/ pic.twitter.com/jO4cqA37sD
— Jordy Cohen, MD, MSCE (@jordy_bc) December 28, 2020